...Allergan's growth outlook, profitability and strong product portfolio could support higher ratings than the current 'BBB¡'. Positive rating momentum could materialize over the next 12¡18 months, depending on the firm's M&A activity....
Navigator
Enter the keyword(s) you would like to search for within this report:
Fitch Affirms Allergan at 'BBB-'; Outlook Revised to Stable – 2016/04/07 – US$ 149.00
Fitch: New Treasury Rules Sink Pfizer-Allergan Deal – 2016/04/07 – US$ 149.00
Fitch: Innovation, Regulation & Political Risks Key 2017 Themes for Global Pharma and Biotech – 2016/11/30 – US$ 149.00
Fitch Affirms Allergan at 'BBB-'; Outlook Stable – 2016/12/08 – US$ 149.00
Fitch Rates Allergan's Euro Notes Offering 'BBB-'; Outlook Stable – 2017/05/23 – US$ 149.00
Fitch Wire+: Generic Pharma Ratings Face Pressure From M&A Surge – 2015/08/13 – US$ 999.00
2017 Outlook: Global Pharma and Biotech – 2016/11/30 – US$ 750.00
Allergan plc - Ratings Navigator – 2016/12/20 – US$ 500.00
Fitch: Generic Pharma Ratings Face Pressure From M&A Surge – 2015/08/13 – US$ 149.00
Fitch Places Allergan's Ratings on Positive Watch Following Pfizer Merger Announcement – 2015/11/23 – US$ 149.00
Fitch Research—Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.
Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.
Search all our Credit Research from one place.